Current technologies in patients with chronic wounds

POLY 29

Harold Brem, hb2133@columbia.edu, Wound Healing Program, Division of Plastic Surgery, Department of Surgery, Columbia University Medical Center, College of Physcians & Surgeons, 5141 Broadway, Room 3-020, New York, NY 10032
Extensive studies in animal and human tissue have led to FDA approval of polyanhydride polymers in humans. A local, sustained release of growth factors to chronic wounds, particularly diabetic foot ulcers, may reduce morbidity and mortality in these patients. As an example, local delivery of angiogenic therapy via Adenovirus (ADV) healed murine diabetic wounds on average 6.6 days sooner than controls, significantly accelerated epithelialization, and increased the number of cells and blood vessels in granulation tissue. Treatment with ADV/VEGF (5x10^10) produced statistically significant (p=0.005) increase in tensile stiffness compared to vehicle controls. However, it is not clear whether an ADV delivery system is optimal. Alternatively, polymers, e.g. polyanhydride, can be used for sustained release. Our objective is to describe the characteristics of a polymer delivery system for local sustained release of growth factors to a wound.
 

Polymer Science of Everyday Things
8:25 AM-12:00 PM, Sunday, August 19, 2007 Westin Boston Waterfront -- Otis, Oral

Division of Polymer Chemistry

The 234th ACS National Meeting, Boston, MA, August 19-23, 2007